NetWorth
LeaderPortfolio
Reddy
M.Satyanarayana Reddy
Rank #1516
INDIA•Healthcare•Pharmaceuticals

M.Satyanarayana Reddy

Net Worth
$2.735B
0% (24h)
M. Satyanarayana Reddy is a pharmaceutical billionaire and the Founder, Chairman, and Managing Director of MSN Group of Companies, headquartered in Hyderabad, India. He founded MSN Laboratories in 2003 with the mission of making high-quality medicines affordable. His career began in 1990, and he has been credited with developing various new molecules, holding numerous patents, and receiving prestigious awards for his contributions to the pharmaceutical industry.

How to read M.Satyanarayana Reddy's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For M.Satyanarayana Reddy, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.735B alongside global rank #1516, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (INDIA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Dr. M. Satyanarayana Reddy, often known as Dr. MSN, was born in 1970 in Telangana, India. He completed his senior secondary education in Hyderabad before pursuing a Doctor of Philosophy (Ph.D.) in Organic Chemistry from Osmania University.

Rise to Success

Dr. Reddy began his career as a scientist. In 2003, he founded MSN Laboratories with the goal of providing affordable generic medicines. Over the years, MSN Group expanded to include five privately held companies, with 16 manufacturing plants across the US, India, and Myanmar. In 2020, MSN started producing Favipiravir, a low-priced version of the COVID-19 drug, under the brand name Favilow.

Key Business Strategies

MSN Laboratories focuses on research-driven and affordable medicines, particularly in oncology and cardiology. The company has expanded significantly, and it holds 690 patents in India and other countries. The company has also entered into a license agreement with the Defence Research & Development Organisation (DRDO) for manufacturing, distribution and marketing of Covid-19 drug 2-Deoxy-D-Glucose (2-DG) in India. MSN's success is built on its commitment to developing new molecules and bringing them to market swiftly.

Philanthropy

During the COVID-19 pandemic, Dr. MSN Reddy sent Rs. 5 crores worth of medicine and equipment to the chief minister of Telangana to combat the pandemic.

Career Timeline

2020

Launched Favilow

Introduced a low-priced version of the COVID-19 drug Favipiravir.

2003

Founded MSN Laboratories

Established the company with the mission of providing affordable generic medicines.

Philanthropic Impact

Healthcare$0.6

COVID-19 Relief

Contributed medicine and equipment to Telangana's chief minister during the pandemic.

Key Business Ventures & Holdings

CompanyStakeValue
MSN Laboratories——

Net Worth History

In-Depth Analysis

Early Life

Dr. M. Satyanarayana Reddy, often known as Dr. MSN, was born in 1970 in Telangana, India. He completed his senior secondary education in Hyderabad before pursuing a Doctor of Philosophy (Ph.D.) in Organic Chemistry from Osmania University.

Rise to Success

Dr. Reddy began his career as a scientist. In 2003, he founded MSN Laboratories with the goal of providing affordable generic medicines. Over the years, MSN Group expanded to include five privately held companies, with 16 manufacturing plants across the US, India, and Myanmar. In 2020, MSN started producing Favipiravir, a low-priced version of the COVID-19 drug, under the brand name Favilow.

Key Business Strategies

MSN Laboratories focuses on research-driven and affordable medicines, particularly in oncology and cardiology. The company has expanded significantly, and it holds 690 patents in India and other countries. The company has also entered into a license agreement with the Defence Research & Development Organisation (DRDO) for manufacturing, distribution and marketing of Covid-19 drug 2-Deoxy-D-Glucose (2-DG) in India. MSN's success is built on its commitment to developing new molecules and bringing them to market swiftly.

Philanthropy

During the COVID-19 pandemic, Dr. MSN Reddy sent Rs. 5 crores worth of medicine and equipment to the chief minister of Telangana to combat the pandemic.

Data Sources & Methodology

Figures for M.Satyanarayana Reddy are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom